Admed Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 23-10-2024
- Paid Up Capital ₹ 1.00 M
as on 23-10-2024
- Company Age 4 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 10.00 Cr
as on 23-10-2024
- Revenue 292.59%
(FY 2023)
- Profit 1149.95%
(FY 2023)
- Ebitda 5065.53%
(FY 2023)
- Net Worth 1287.23%
(FY 2023)
- Total Assets 30.91%
(FY 2023)
About Admed Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹10.00 Cr.
Ashutosh Goel, Mayank Goel, and Surinder Sharma serve as directors at the Company.
- CIN/LLPIN
U36900DL2020PTC372472
- Company No.
372472
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Oct 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Admed Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mayank Goel  | Director | 30-Oct-2020 | Current |
| Ashutosh Goel | Director | 30-Oct-2020 | Current |
| Surinder Sharma | Director | 15-Jul-2023 | Current |
Financial Performance and Corporate Structure Insights of Admed Pharma.
Admed Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 292.59% increase. The company also saw a substantial improvement in profitability, with a 1149.95% increase in profit. The company's net worth Soared by an impressive increase of 1287.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Admed Pharma?
In 2023, Admed Pharma had a public holding of 37.50%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Palohma Healthcare Private LimitedActive 1 year 7 monthsAshutosh Goel and Mayank Goel are mutual person
- Warner (India) Pharma Private LimitedActive 17 years 7 days
Ashutosh Goel and Mayank Goel are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 28 Feb 2022 | ₹5.00 Cr | Open |
Axis Bank Limited Creation Date: 25 Feb 2022 | ₹5.00 Cr | Open |
How Many Employees Work at Admed Pharma?
Admed Pharma has a workforce of 70 employees as of Aug 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Admed Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Admed Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
